Log In
BCIQ
Print this Print this
 

ReS9-S

  Manage Alerts
Collapse Summary General Information
Company reMYND N.V.
DescriptionSmall molecule against an undisclosed target that prevents neurotoxicity associated with alpha-synuclein (SNCA)
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat Parkinson's disease (PD)
Regulatory Designation
PartnerRoche

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

$644.9M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/13/2010

Undisclosed

Undisclosed

$644.9M

Get a free BioCentury trial today